Abstract
OBJECTIVE: To investigate the weight-reducing effect of cimetidine in overweight patients with Type 2 diabetes.
DESIGN: A 12-week clinical intervention study of 400 mg cimetidine prescribed three times daily in a randomised, double-blind, placebo-controlled design.
SUBJECTS: Forty-three overweight patients with Type 2 diabetes (age 18–65 y, body mass index (BMI) 27.2–48.2 kg/m2).
MEASUREMENTS: Body weight, BMI, body fat, waist and hip circumference, waist/hip ratio, blood pressure, fasting blood glucose, HbA1c, plasma concentrations of insulin, insulin/glucose ratio and lipids at the start and after 12 weeks, and daily recordings of appetite.
RESULTS: Subjects given cimetidine (n=19) and placebo (n=24) lost 5.0±2.2 kg (mean±s.d.) and 1.3±1.1 kg, respectively. Significant reductions were observed in appetite, body fat (29.9±6.6% to 25.3±7.4%), waist circumference (111.5±10.3 cm to 107.4±10.6 cm), waist/hip ratio (0.96±0.08 to 0.94±0.08), and systolic and diastolic blood pressure (reductions of 6.9±11.4 mm Hg and 6.0±6.6 mm Hg, respectively) in cimetidine group only. Significant decreases in fasting concentrations of blood glucose, HbA1c, plasma insulin, insulin/glucose ratio, plasma triglycerides and a significant increase in plasma high-density lipoprotein cholesterol were observed in the cimetidine group only.
CONCLUSIONS: Cimetidine reduces appetite and body weight, and improves metabolic control in overweight subjects with Type 2 diabetes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Støa-Birketvedt, G., Paus, P., Ganss, R. et al. Cimetidine reduces weight and improves metabolic control in overweight patients with Type 2 diabetes. Int J Obes 22, 1041–1045 (1998). https://doi.org/10.1038/sj.ijo.0800721
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0800721